Diagnostic Financings Are Robust, Fueled by COVID-19 and Precision Medicine

 

Published in MedTechStrategist

Authors: Wendy Diller

Abstract:

Private investors poured more than $8 billion into diagnostics companies between January 2020 and September 30, 2021, envisioning myriad opportunities for innovative COVID-19 testing technologies and precision medicine tests that help optimize individual treatment regimens.

View full article

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    99 High St. Suite 2900, Boston, MA 02110
    (617) 431-4886